Description: Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.
Home Page: www.raceoncology.com
RAC Technical Analysis
Gateway, 1 Macquarie Place
Sydney,
NSW
2000
Australia
Phone:
61 2 8051 3043
Officers
| Name | Title |
|---|---|
| Mr. Phillip R. Lynch | CEO, MD & Director |
| Dr. Daniel Tillett | Chief Scientific Officer & Exec. Director |
| Ms. Christina Manfre | Chief Financial Officer |
| Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP | Interim Chief Medical Officer |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.5982 |
| Price-to-Sales TTM: | 467.7607 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |